Hair loss following COVID-19 infection - the state of current knowledge and treatment approaches.
DOI:
https://doi.org/10.12775/JEHS.2023.13.01.037Keywords
SARS-CoV-2, hair, Nutrition, drug treatmentAbstract
Introduction: Telogen effluvium is a non-scarring hair loss that can occur after COVID-19 infection. It usually occurs after about 3 months, causes diffused hair loss and lasts up to 6 months. The purpose of this narrative review is to collect and summarize the effects of potential methods to promote hair regrowth in patients after COVID-19 infection.
Material and method: The article reviews available in PubMed and ResearchGate databases, studies on telogen effluvium and SARS-CoV-2. Due to the limited literature, articles on telogenetic hair loss progressing independently of COVID-19 were also included in the review.
Results: Hair loss after COVID-19 infection occurs in almost 30% of patients. This is likely related to pro-inflammatory cytokines released during infection and the pro-thrombotic effect of the virus. Telogen effluvium is the most common type of alopecia occurring after COIVD-19 infection - about 86% of all cases. It affects women more often than men. It seems that its severity may correlate with the severity of the infection. Other than female gender and a history of chronic disease, it is unlikely to find any other contributing factors. Effective treatments seem to include the use of oral supplements such as vitamin D, polyunsaturated fatty acids and zinc. In addition, topical application of minoxidil and high-platelet plasma treatments have shown good outcomes.
Conclusions: Given the fairly common occurrence of hair loss after COVID-19 infection, it seems reasonable to seek the most effective strategies for its treatment. At present, it appears that the best results are obtained by combining different treatment approaches.
References
Bedocs LA, Bruckner AL. Adolescent hair loss. Curr Opin Pediatr. sierpień 2008;20(4):431–5.
Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low-level laser (light) therapy (LLLT) for treatment of hair loss: LLLT FOR HAIR REGROWTH. Lasers Surg Med. luty 2014;46(2):144–51.
Malkud S. Telogen Effluvium: A Review. J Clin Diagn Res. wrzesień 2015;9(9):WE01-03.
Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 27 maj 2020;12(5):e8320.
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. czerwiec 2020;8(6):e46–7.
Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N, i in. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. marzec 1989;20(3):395–407.
Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. marzec 1993;129(3):356–63.
Diotallevi F, Campanati A, Bianchelli T, Bobyr I, Luchetti MM, Marconi B, i in. Skin involvement in SARS-CoV-2 infection: Case series. J Med Virol. listopad 2020;92(11):2332–4.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. czerwiec 2020;80(6):607–13.
Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Ir J Med Sci. 2022;191(4):1677–81.
Moreno‐Arrones OM, Lobato‐Berezo A, Gomez‐Zubiaur A, Arias‐Santiago S, Saceda‐Corralo D, Bernardez‐Guerra C, i in. SARS‐CoV‐2‐induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol. marzec 2021;35(3):e181–3.
Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, i in. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. styczeń 2021;27(1):89–95.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, i in. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 16 styczeń 2021;397(10270):220–32.
Starace M, Iorizzo M, Sechi A, Alessandrini AM, Carpanese M, Bruni F, i in. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. grudzień 2021;5:11–8.
Abdulwahab RA, Aldajani BM, Natto NK, Janabi AM, Alhijaili OI, Faqih NT, i in. Prevalence of Hair Loss After COVID-19 Infection in Makkah Region, Saudi Arabia. Cureus [Internet]. 18 wrzesień 2022 [cytowane 8 listopad 2022];14(9). Dostępne na: https://www.cureus.com/articles/110534-prevalence-of-hair-loss-after-covid-19-infection-in-makkah-region-saudi-arabia
Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 31 styczeń 2017;7(1):1–10.
Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination. J Am Acad Dermatol. wrzesień 2014;71(3):415.e1-415.e15.
Høier ATZB, Chaaban N, Andersen BV. Possibilities for Maintaining Appetite in Recovering COVID-19 Patients. Foods. luty 2021;10(2):464.
Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc [Internet]. Washington (DC): National Academies Press (US); 2001 [cytowane 8 listopad 2022]. Dostępne na: http://www.ncbi.nlm.nih.gov/books/NBK222310/
Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb). 13 grudzień 2018;9(1):51–70.
Livingstone C. Fat-soluble vitamins in nutrition support. W: Advanced Nutrition and Dietetics in Nutrition Support [Internet]. John Wiley & Sons, Ltd; 2018 [cytowane 8 listopad 2022]. s. 144–54. Dostępne na: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118993880.ch3.5
Naziroglu M, Kokcam I. Antioxidants and lipid peroxidation status in the blood of patients with alopecia. Cell Biochem Funct. wrzesień 2000;18(3):169–73.
Beoy LA, Woei WJ, Hay YK. Effects of Tocotrienol Supplementation on Hair Growth in Human Volunteers. Trop Life Sci Res. grudzień 2010;21(2):91–9.
Pierce JD, Shen Q, Cintron SA, Hiebert JB. Post-COVID-19 Syndrome. Nurs Res. 1 kwiecień 2022;71(2):164–74.
Vimaleswaran KS, Forouhi NG, Khunti K. Vitamin D and covid-19. BMJ. 4 marzec 2021;372:n544.
Jolliffe DA, Camargo CA, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, i in. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials [Internet]. medRxiv; 2020 [cytowane 5 listopad 2022]. s. 2020.07.14.20152728. Dostępne na: https://www.medrxiv.org/content/10.1101/2020.07.14.20152728v3
Demay MB. The hair cycle and Vitamin D receptor. Archives of Biochemistry and Biophysics. 1 lipiec 2012;523(1):19–21.
Nayak K, Garg A, Mithra P, Manjrekar P. Serum vitamin D3levels and diffuse hair fall among the student population in South India: A case–control study. International Journal of Trichology. 10 styczeń 2016;8(4):160.
Hassan GFR, Sadoma MET, Elbatsh MM, Ibrahim ZA. Treatment with oral vitamin D alone, topical minoxidil, or combination of both in patients with female pattern hair loss: A comparative clinical and dermoscopic study. J Cosmet Dermatol. wrzesień 2022;21(9):3917–24.
Patel DP, Swink SM, Castelo-Soccio L. A Review of the Use of Biotin for Hair Loss. SAD. 2017;3(3):166–9.
Kang JI, Yoon HS, Kim SM, Park JE, Hyun YJ, Ko A, i in. Mackerel-Derived Fermented Fish Oil Promotes Hair Growth by Anagen-Stimulating Pathways. Int J Mol Sci. 14 wrzesień 2018;19(9):2770.
Le Floc’h C, Cheniti A, Connétable S, Piccardi N, Vincenzi C, Tosti A. Effect of a nutritional supplement on hair loss in women. J Cosmet Dermatol. marzec 2015;14(1):76–82.
Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. lipiec 2002;27(5):396–404.
Popescu MN, Berteanu M, Beiu C, Popa LG, Mihai MM, Iliescu MG, i in. Complementary Strategies to Promote Hair Regrowth in Post-COVID-19 Telogen Effluvium. CCID. 22 kwiecień 2022;15:735–43.
Cheung EJ, Sink JR, English Iii JC. Vitamin and Mineral Deficiencies in Patients With Telogen Effluvium: A Retrospective Cross-Sectional Study. J Drugs Dermatol. 1 październik 2016;15(10):1235–7.
Plonka PM, Handjiski B, Popik M, Michalczyk D, Paus R. Zinc as an ambivalent but potent modulator of murine hair growth in vivo- preliminary observations. Exp Dermatol. listopad 2005;14(11):844–53.
Siavash M, Tavakoli F, Mokhtari F. Comparing the Effects of Zinc Sulfate, Calcium Pantothenate, Their Combination and Minoxidil Solution Regimens on Controlling Hair Loss in Women: A Randomized Controlled Trial. J Res Pharm Pract. czerwiec 2017;6(2):89–93.
MacFarquhar JK, Broussard DL, Melstrom P, Hutchinson R, Wolkin A, Martin C, i in. Acute selenium toxicity associated with a dietary supplement. Arch Intern Med. 8 luty 2010;170(3):256–61.
Jarosza M, Rychlik E, Stoś K, Charzewskiej J. Normy żywienia dla populacji Polski i ich zastosowanie. :465.
Jiang Y, Shi Q, Huang Y, Li J, Xie H, Liu F. Relationship between the exercise and severity of androgenic alopecia. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 28 lipiec 2021;46(7):725–30.
Deglesne PA, Arroyo R, Ranneva E, Deprez P. In vitro study of RRS HA injectable mesotherapy/biorevitalization product on human skin fibroblasts and its clinical utilization. Clin Cosmet Investig Dermatol. 2016;9:41–53.
Herreros FOC, Moraes AM de, Velho PENF. Mesotherapy: a bibliographical review. An Bras Dermatol. luty 2011;86(1):96–101.
Konda D, Thappa DM. Mesotherapy: What is new? IJDVL. 1 styczeń 2013;79:127.
Fertig R m., Gamret A c., Cervantes J, Tosti A. Microneedling for the treatment of hair loss? Journal of the European Academy of Dermatology and Venereology. 2018;32(4):564–9.
Khattab FM, Rady A, Khashaba SA. Recent modalities in treatment of telogen effluvium: Comparative study. Dermatologic Therapy. 2022;35(10):e15720.
Dargie HJ, Dollery CT, Daniel J. MINOXIDIL IN RESISTANT HYPERTENSION. The Lancet. 10 wrzesień 1977;310(8037):515–8.
Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol. listopad 1979;101(5):593–5.
Minoxidil and its use in hair disorders: a review | DDDT [Internet]. [cytowane 6 listopad 2022]. Dostępne na: https://www.dovepress.com/minoxidil-and-its-use-in-hair-disorders-a-review-peer-reviewed-fulltext-article-DDDT
Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. czerwiec 2022;33(4):1896–906.
Pekmezci E, Turkoğlu M, Gökalp H, Kutlubay Z. Minoxidil Downregulates Interleukin-1 Alpha Gene Expression in HaCaT Cells. Int J Trichology. czerwiec 2018;10(3):108–12.
Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol. 1 marzec 1988;37(5):867–74.
Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. luty 2002;46(2):309–12.
Emer J. Platelet-Rich Plasma (PRP): Current Applications in Dermatology. Skin Therapy Lett. wrzesień 2019;24(5):1–6.
Roohaninasab M, Goodarzi A, Ghassemi M, Sadeghzadeh-Bazargan A, Behrangi E, Najar Nobari N. Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. Dermatol Ther. marzec 2021;34(2):e14768.
İşlek A, Karaaslan E, Şimşek S, Merve Çetin F. Platelet-Rich Plasma Treatment for Accelerated Androgenetic Alopecia Pattern Hair Loss After COVID-19 Infection: A Case Series. J Cosmet Dermatol. luty 2022;21(2):590–4.
4 Treatments for COVID-Related Hair Loss [Internet]. Riverchase Dermatology. 2022 [cytowane 6 listopad 2022]. Dostępne na: https://www.riverchasedermatology.com/blog/4-treatments-for-covid-related-hair-loss/
Schindl A, Schindl M, Pernerstorfer-Schön H, Schindl L. Low-intensity laser therapy: a review. J Investig Med. wrzesień 2000;48(5):312–26.
Zarei M, Wikramanayake TC, Falto-Aizpurua L, Schachner LA, Jimenez JJ. Low level laser therapy and hair regrowth: an evidence-based review. Lasers Med Sci. luty 2016;31(2):363–71.
Amer M, Nassar A, Attallah H, Amer A. Results of low‐level laser therapy in the treatment of hair growth: An Egyptian experience. Dermatologic Therapy [Internet]. maj 2021 [cytowane 7 listopad 2022];34(3). Dostępne na: https://onlinelibrary.wiley.com/doi/10.1111/dth.14940
Ghanaat M. Types of Hair Loss and Treatment Options, Including the Novel Low-Level Light Therapy and Its Proposed Mechanism: Southern Medical Journal. wrzesień 2010;103(9):917–21.
Essam R, Ehab R, Al-Razzaz R, Khater MW, Moustafa EA. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor? J Cosmet Dermatol. grudzień 2021;20(12):3727–9.
Rossi A, Magri F, Michelini S, Caro G, Di Fraia M, Fortuna MC, i in. Recurrence of alopecia areata after covid-19 vaccination: A report of three cases in Italy. J Cosmet Dermatol. grudzień 2021;20(12):3753–7.
Birkett L, Singh P, Mosahebi A, Dhar S. Possible Associations Between Alopecia Areata and COVID-19 Vaccination and Infection. Aesthet Surg J. 20 czerwiec 2022;42(11):NP699–702.
Sookaromdee P, Wiwanitkit V. Response to: Possible Associations Between Alopecia Areata and COVID-19 Vaccination and Infection. Aesthet Surg J. 1 lipiec 2022;sjac176.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Gracjan Rudziński, Natalia Kusak, Kinga Brzuszkiewicz, Borys Łozowski, Arkadiusz Grunwald, Weronika Dalmata
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 817
Number of citations: 0
